1. trastuzumab deruxtecan (Enhertu) n.d. 〈https://www.scottishmedicines.org.uk/medicines-advice/trastuzumab-deruxtecan-enhertu-full-smc2608/〉 (accessed April 27, 2024).
2. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Engl J Med,2022
3. FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer: Trastuzumab Deruxtecan (T-DXd) | Memorial Sloan Kettering Cancer Center n.d. 〈https://www.mskcc.org/news/trastuzumab-deruxtecan-t-dxd-treating-her2-low-breast-cancer〉 (accessed April 27, 2024).
4. 8 May 2024 - Future Cancer: NICE medicines appraisal (Enhertu) - Oral evidence - Committees - UK Parliament n.d. 〈https://committees.parliament.uk/event/21529/formal-meeting-oral-evidence-session/〉 (accessed May 12, 2024).
5. Trastuzumab Deruxtecan (Enhertu);Deruxtecan;Can J Health Technol,2023